Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Return on Capital Employed (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Return on Capital Employed for 4 consecutive years, with 0.36% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed rose 27.0% to 0.36% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.36% through Dec 2025, up 27.0% year-over-year, with the annual reading at 0.49% for FY2025, 16.0% up from the prior year.
  • Return on Capital Employed hit 0.36% in Q4 2025 for Taysha Gene Therapies, down from 0.34% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 2.64% in Q3 2023 to a low of 2.92% in Q2 2023.
  • Historically, Return on Capital Employed has averaged 0.77% across 4 years, with a median of 0.55% in 2024.
  • Biggest five-year swings in Return on Capital Employed: skyrocketed 241bps in 2023 and later plummeted -318bps in 2024.
  • Year by year, Return on Capital Employed stood at 2.9% in 2022, then skyrocketed by 83bps to 0.49% in 2023, then dropped by -29bps to 0.63% in 2024, then soared by 43bps to 0.36% in 2025.
  • Business Quant data shows Return on Capital Employed for TSHA at 0.36% in Q4 2025, 0.34% in Q3 2025, and 0.45% in Q2 2025.